UroGen Pharma Reports Q3 Earnings Miss on EPS and Revenue
UroGen Pharma (URGN) reported third-quarter financial results that fell short of market expectations. The company posted a GAAP earnings per share (EPS) of -$0.03, missing estimates by $0.13. Total revenue for the quarter reached $89 million, representing a significant year-over-year increase of 223.9%, yet still missed consensus estimates by approximately $0.91 million. Despite the earnings miss, the company showed strong operational growth in its commercial footprint. Activated sites of care increased to 1,538 from 1,444 at the end of the previous period, while unique ZUSDURI prescribers grew to 662, up from 452.
Tickers: $URGN
Topics: earnings miss financial results prescriber metrics revenue growth
Read the full article at Seeking Alpha
Part of the story Waste Management Q3 Earnings Analysis: Strong Free Cash Flow Offsets EPS Miss (4 articles)